Advertisement

Topics

Icon Bioscience, Inc. Company Profile

06:36 EST 16th December 2018 | BioPortfolio

Icon Bioscience, Inc., (IBI), is a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals based on its Verisome(TM) drug delivery technology. IBI is developing a broad portfolio of clinically superior specialty pharmaceuticals targeting major ophthalmic indications including macular edema, glaucoma, age-related macular degeneration and cataract surgery inflammation. In addition to IBI-10090, which will begin pivotal clinical trials in the next few months, IBI-20089 has completed its initial clinical trial in patients with cystoid macular edema associated with retinal vein occlusion. It is designed to deliver triamcinolone for up to a year with a single intravitreal injection. IBI anticipates two more products will enter clinical trials in early 2011. IBI has also entered into agreements with multiple international pharmaceutical companies interested in the use of the Verisome technology for its own ophthalmic products. For more information please refer to www.iconbioscience.com


News Articles [381 Associated News Articles listed on BioPortfolio]

R B and Pop Icon Valerie Simpson and Pulitzer Prize-Winning Composer Melinda Wagner Receive Top ...

NEW YORK, Dec. 12, 2018 /PRNewswire/ -- The ASCAP Foundation honored R&B and pop icon Valerie Simpson with its George M. Cohan Friars Foundation Award Read more...

Robotics, automation to play a ‘fundamental role’ in Icon’s continued success: Q2 earnings call

Robotics and automation will help improve the clunky and expensive clinical trial process, says Icon CEO â as the company continues to evaluate potential opportunities to improve efficiency.

Arix Bioscience Plc - Arix Bioscience announces first VIPE investment

Arix Bioscience Plc - Arix Bioscience announces first VIPE investment PR Newswire London, August 5 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATIO...

Icon launches technology for adaptive clinical trial design

Icon has launched an integrated technology platform for the design, simulation, and analysis of adaptive clinical trials.

Aytu BioScience, Inc.: Aytu BioScience Announces Pricing of $13.2 Million Underwritten Public Offering

ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant ...

ICON CEO: CROs Must Be Aware Of Threat Posed By Big Tech

ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of...   

New Icon collab looks to meet demand for real world evidence

Icon and Practice Fusion have teamed up to meet the expanding demand for real world evidence â and aim to transform the way research is conducted.

Aytu BioScience, Inc.: Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant...

PubMed Articles [78 Associated PubMed Articles listed on BioPortfolio]

Quality assurance tests for the Gamma Knife Icon™ image guidance system.

The Gamma Knife Icon™ comes with an image guidance system for tracking patient motion and correcting for inter- and intrafractional shifts, mainly used with frameless thermoplastic immobilization. T...

A Phase 1, Open-Label, Dose-Escalation Trial to Investigate Safety and Tolerability of Single Intravitreous Injections of ICON-1 Targeting Tissue Factor in Wet AMD.

This phase 1 study evaluated the safety and tolerability of single intravitreous injections (IVIs) of ICON-1 (Iconic Therapeutics, South San Francisco, CA) in patients with neovascular age-related mac...

A transformative icon for modern perinatology.

Editorial: Bioscience of D-amino Acid Oxidase From Biochemistry to Pathophysiology.

Performance characterization of an integrated cone-beam CT system for dedicated gamma radiosurgery.

This work describes the performance characterization of a cone-beam CT guided radiosurgery device, the Gamma Knife Icon .

Clinical Trials [17 Associated Clinical Trials listed on BioPortfolio]

The Effect of ICON Treatment on WPL With Patients After Fixed Orthodontic Appliances

The aim of this study is to determine the effect of ICON on White spot lesions compared to CPP-ACPF plus.

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept ...

Randomized Controlled Crossover Comparison of Icon Underwear to Disposable Pads

This is a randomized cross over trial to compare quality of life and product performance between Icon reusable underwear versus standard disposable pad in patients with mild to moderate ur...

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholi...

Non-invasive Monitor in Endoscopic Invasive Procedure

We include the patients who need painless invasive endoscopic precedure, we collect the dempgraphic data and apply the non-invasive device ICON on patients during the who procedure.

Companies [339 Associated Companies listed on BioPortfolio]

Icon Bioscience, Inc.

Icon Bioscience, Inc., (IBI), is a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals based on its Verisome(TM) drug...

Icon Bioscience Inc.

Icon Bioscience, Inc. is a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its pa...

ICON Clinical Research

ICON was founded in 1990 by a group of experienced professionals, who were dedicated to providing the pharmaceutical and biotechnology industries with exceptional clinical research and biometric servi...

ICON Eyecare

ICON Eyecare is a leading surgical and medical eye care provider, based out of Denver, CO. Since 1999, ICON has been building a Center of Ophthalmology Excellence empowered by an ...

ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic devel...

More Information about "Icon Bioscience, Inc." on BioPortfolio

We have published hundreds of Icon Bioscience, Inc. news stories on BioPortfolio along with dozens of Icon Bioscience, Inc. Clinical Trials and PubMed Articles about Icon Bioscience, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Icon Bioscience, Inc. Companies in our database. You can also find out about relevant Icon Bioscience, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record